Bioprogress - FTSE 100 company in the making

Sometimes it's interesting to look back a few years and a/ see who knew what and when (who was NM2??) and b/ how companies work together to "mesh" their expertises.

Red Dog - 14 Aug'01 - 19:51 - 19 of 149

... The fibre furnace business will make record pre-tax profits this yeay, but the main push will be in the subsidery InGel technologies. They are only now waking up to and assessing the potential of this technology. ...


NM2 - 4 Sep'01 - 15:02 - 25 of 149

Red Dog,

the main push will be in the subsidiary InGel technologies

When you next speak to Ian Balchin, ask him for the name of the company who gave SEO the idea of InGel.

Ask him whether the company concerned briefed SEO under an NDA.

And ask him whether he expects them to sue should SEO's plans get nearer to fruition.

NM


MaxInvestor - 7 Dec'01 - 00:01 - 101 of 149

Got to be drastically rerated now. Minnow in with US Co with $40billion revenues!!!!!!!!

RNS Number:2810O
Stanelco PLC
6 December 2001


Notification of Class 2 transaction


AVS No:


Name of Company: STANELCO PLC


Stanelco plc (Stanelco) has entered into contract with R.P. Scherer Corporation
(Scherer) to sell ten percent (10%) of the enlarged equity of its subsidiary,
InGel Technologies Limited (InGel).

InGel is a company created by Stanelco to commercialise its capsule making
technology and has not previously traded.

Scherer is one of the world's premier drug delivery companies and has the
leading global position in the softgel capsule technology. Scherer is part of
the Pharmaceutical Technologies & Services division of Cardinal Health, Inc.
Cardinal is a leading provider of products and services supporting the
health-care industry. Cardinal Health companies develop, manufacture, package
and market products for patient care; develop drug-delivery technologies;
distribute pharmaceuticals, medical, surgical and laboratory supplies; and
offer consulting and other services that improve quality and efficiency in
health care. The company, which is headquartered in Dublin, Ohio, employs more
than 49,000 people on five continents and produces annual revenues of more
than US$40 billion.

The consideration for the sale of these shares in InGel is:

(i) For the first five percent (5%) of the enlarged equity
Scherer will make a cash payment of five hundred and sixty-three thousand
three hundred and sixty-five pounds sterling (#563,365).

(ii) For the second five percent (5%) of the enlarged equity,
due in 36 months time, the consideration shall be equivalent to the mid-market
price, at that time, of 3% of Stanelco plc. For illustration only, this figure
would be five hundred and sixty-six thousand six hundred and thirty-four
pounds sterling (#566,634) based upon a Stanelco plc share price of 2.75
pence.

The proceeds from the sale will be used by InGel to further develop Stanelco's
proprietary technology, under licence, for manufacturing liquid-filled
capsules for pharmaceutical applications. InGel has also entered into licence
agreements with Scherer giving InGel access to certain of Scherer's
intellectual property and giving Scherer rights to use both the Stanelco and
InGel technology for pharmaceutical applications in return for royalties.

The commercial success of InGel is dependant upon the outcome of the
development work to be carried out. It is intended that if successful Stanelco
would manufacture production equipment to satisfy market demand.

InGel also expects to receive equipment (valued at approximately #100k)
together with services and expertise from Scherer in support of the
development work

The service contracts of Stanelco's directors remain unchanged. InGel
currently has two directors, Ian Balchin, who is also chief executive and a
director of Stanelco plc and Barrie Hozier who is also finance director and
company secretary of Stanelco plc. The company expects to appoint a third
director from Scherer. It is not anticipated that the directors will receive
any additional remuneration from InGel.


Ends.


Red Dog - 7 Dec'01 - 07:54 - 121 of 149


I have given thought to yesterday's announcement. First of all, they will NOT now be able to take the Company private. Also R.P.Scherer Corporation will put a Director on the Board. This will have the effect of re-generating certain aspects of the Company, such at the lenth of time to announce Interim or Prelim accounts and informing the shareholders to what is going on.

THe exchange of technologe between the companies will also greatly improve the time of release of products.In all this could not be a better deal for Stanelco.

NOW for the best. Other pharmaceutical companies can only get on board by buying existing shares. The two main Directors could sell some of their shares or they must enter the market place.

Believe me, they will if In-Gel proves to be commercial as I think it will. So to you all, my share expectation of 7p is now a reality and in the next twelve months 10p to 12p is not out of the question. SO BUY WHILE YOU CAN.


MaxInvestor - 7 Dec'01 - 08:16 - 122 of 149

Pictures of the pill are on the website!!! www.stanelcoplc.com.

Topping up again!

British Invention leads to new pharmaceutical dose-form

Stanelco plc, which specialises in the use of high-power radio waves to rapidly heat and weld material, has signed a deal with drug delivery company R.P. Scherer to jointly complete development and commercialise Stanelco's patented capsule making technology. This follows significant progress in developing the technology to the point of proof-of-concept during a two-year evaluation and development programme between the companies.

A newly created company known as InGel Technologies will develop the commercial process for manufacturing liquid-filled capsules, initially, for pharmaceutical applications. "Our objectives are simple", said Stanelco's chief executive, Ian Balchin, "To determine the full commercial viability of the process and then to help Scherer reap the benefits as soon as possible." Stanelco's process enables capsules to be made rapidly from almost any ingestible materials, including plant extracts, opening up the scope to design new drug delivery systems with a wide range of applications.

"We decided early on that securing a route to market with an industry partner was the best way forward for us. We have been working with R.P. Scherer for two years and have built up a mutual respect and trust at all levels between our organisations. The choice of partners is crucial for the success of this project. Scherer is the world's largest producer of this kind of capsule, in a market estimated to be worth around £1.2bn annually. The relationship with R.P. Scherer substantially lowered the risks for InGel through both the provision of a route to market and unequalled access to intellectual property. The other key aspect for us was ensuring that we protected our own inventions with patents and in commercial agreements. In this regard we worked with Accentus, a wholly owned subsidiary of AEA Technology plc, as a partner in the commercialisation to protect our process with a suite of worldwide patents. With Accentus we jointly developed the business plan, which has led to the deal with Scherer." Accentus will receive a share of Stanelco's future licence revenue over the next 8 years. As part of the deal Scherer will purchase a total 10% equity interest in InGel Technologies Ltd for a total consideration of £1.23M, which will be used to further develop the technology. Scherer has also purchased a 3% interest in Stanelco plc for £566k.

RF technology is already a well-accepted process in the Pharmaceutical industry - being used to attach foils to blister packs - it sterilises as it seals and so is highly compatible with Pharmaceutical Good Manufacturing Practice (GMP). Other uses of RF Technology include attaching foil seals to food containers such as plastic milk containers and coffee jars and to melt glass to form fibre optic cables.

Notes for Editors Stanelco plc Stanelco plc (www.stanelcoplc.com) is a technology investment business. The people at Stanelco are innovative and have a passion for meeting and exceeding customer expectations. The core of our business is the supply of high technology used in the manufacture of optical fibre. This technology sustains temperatures of greater than 2000 °C for hundreds of hours enabling glass fibre to be manufactured at rates exceeding seventy kilometres per hour.

We are growing our business in three ways:

o Extending our product range.

Traditionally our heating technology was based on zirconia material, two years ago we introduced heating technology based upon the use of graphite. These two technologies now enable us to cover virtually the entire fibre manufacturing market.

o Applying our core technology to new markets.

Our heating technology can be used to fuse materials together in a very controlled way. One application is the manufacture of capsules.

o Investing in new technology opportunities.

Drawing upon the entrepreneurial skills within the group we have been, and continue to evaluate acquisitions and start-up opportunities in new fields. Contact information: Sylvia Leavey: +44 1489 568910

R.P. Scherer

Scherer is one of the world's premier drug delivery companies and has the leading global position in the softgel capsule technology. R.P. Scherer is part of the Pharmaceutical Technologies & Services division of Cardinal Health, Inc. (www.cardinal.com). Cardinal is a leading provider of products and services supporting the health-care industry. Cardinal Health companies develop, manufacture, package and market products for patient care; develop drug-delivery technologies; distribute pharmaceuticals, medical, surgical and laboratory supplies; and offer consulting and other services that improve quality and efficiency in health care. The company, which is headquartered in Dublin, Ohio, employs more than 49,000 people on five continents and produces annual revenues of more than $40 billion. More information about R.P. Scherer and its products can be found at www.rpscherer.com

Accentus plc

Accentus is the Intellectual Property business of AEA Technology plc with over 500 patents and applications within its portfolio. It is actively developing technologies in many industrial sectors including electronics; electricity; oil & gas; power generation; automotive and pharmaceuticals.

Accentus' licensing and product development activities are achieved through market focused idea generation, either in-house using our own team of scientists and engineers or, where commercially beneficial, through joint ventures, technology transfer and partnerships. In addition to this we actively manage intellectual property on behalf of clients to ensure that their IP is well protected and exploited; we also broker licensing deals for clients to ensure they are deriving the greatest possible value from their technology.

We continually seek to expand our portfolio of intellectual property and operate our own schemes to attract ideas from outside of Accentus: InnovationPlus™ - which offers inventors access to the resources needed to commercialise ideas and; UniversityPlus which is a collaborative venture with key Universities for technology exploitation.